ABBV vs CRWV: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and CoreWeave, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-08-06.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
CoreWeave, Inc. · Technology
$89.89
+24.6% upside to fair value
Med Conviction
Grade C+
QuantHub Verdict
CRWV has more upside to fair value
(+24.6%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
CRWV |
| Current Price |
$261.07 |
$89.89 |
| Fair Value Estimate |
$264.30 |
$112.00 |
| Upside to Fair Value |
+1.2%
|
+24.6%
|
| Market Cap |
$461.3B |
$49.0B |
| Forward P/E |
128.0x
|
—
|
| EV / EBITDA |
31.0x
|
26.6x
|
| Price / Sales |
7.3x
|
7.9x
|
| Price / FCF |
22.1x
|
—
|
| Revenue Growth YoY |
+12.4%
|
+111.6%
|
| Gross Margin |
70.7%
|
69.4%
|
| Operating Margin |
27.6%
|
-2.6%
|
| Return on Equity |
68.0%
|
-33.5%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
-21.6%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
CoreWeave is the leading neocloud, a GPU-specialized cloud infrastructure provider built to serve the compute-hungry demands of generative AI training and inference. Since its March 2025 IPO, revenue has scaled roughly 112% year over year to $2.08 billion in the first quarter of 2026, backed by a $99.4 billion contracted revenue backlog and marquee agreements with Microsoft, OpenAI, Meta, Anthrop…
Accumulation Zones
| Metric |
ABBV |
CRWV |
| Zone Low |
$198.23 |
$84.00 |
| Zone High |
$224.66 |
$95.00 |
| In Buy Zone? |
No
|
Yes
|